Halozyme Therapeutics, Inc. (BMV:HALO)
Mexico · Delayed Price · Currency is MXN 1,121.86
+103.35 (10.15%)
At close: Jul 29, 2025
Halozyme Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| 1,179 | 1,015 | 829.25 | 660.12 | 443.31 | 267.59 | Upgrade | |
Revenue Growth (YoY) | 34.97% | 22.44% | 25.62% | 48.91% | 65.66% | 36.53% | Upgrade |
Cost of Revenue | 186.24 | 159.42 | 192.36 | 139.3 | 81.41 | 43.37 | Upgrade |
Gross Profit | 992.43 | 855.91 | 636.89 | 520.81 | 361.9 | 224.23 | Upgrade |
Selling, General & Admin | 167.47 | 154.34 | 149.18 | 143.53 | 50.32 | 45.74 | Upgrade |
Depreciation & Amortization Expenses | 71.05 | 71.05 | 73.77 | 43.15 | - | - | Upgrade |
Research & Development | 71.24 | 79.05 | 76.36 | 66.61 | 35.67 | 34.24 | Upgrade |
Operating Income | 682.67 | 551.48 | 337.57 | 267.53 | 275.9 | 144.26 | Upgrade |
Interest Income | 27.44 | 23.75 | 16.32 | 1.05 | 1.1 | 5.43 | Upgrade |
Interest Expense | -17.98 | -18.1 | -18.76 | -16.95 | -7.53 | -20.38 | Upgrade |
Other Non-Operating Income (Expense) | - | - | 13.2 | -2.71 | -20.96 | - | Upgrade |
Total Non-Operating Income (Expense) | 9.45 | 5.66 | 10.76 | -18.61 | -27.38 | -14.95 | Upgrade |
Pretax Income | 692.13 | 557.13 | 348.33 | 248.92 | 248.52 | 129.3 | Upgrade |
Provision for Income Taxes | 134.85 | 113.04 | 66.74 | 46.79 | -154.19 | 0.22 | Upgrade |
Net Income | 557.28 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade |
Net Income to Common | 557.28 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade |
Net Income Growth | 65.22% | 57.71% | 39.31% | -49.81% | 211.97% | - | Upgrade |
Shares Outstanding (Basic) | 124 | 127 | 132 | 137 | 141 | 136 | Upgrade |
Shares Outstanding (Diluted) | 128 | 129 | 134 | 141 | 147 | 141 | Upgrade |
Shares Change (YoY) | -2.53% | -3.56% | -4.56% | -4.21% | 3.77% | -1.99% | Upgrade |
EPS (Basic) | 4.48 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | Upgrade |
EPS (Diluted) | 4.37 | 3.43 | 2.10 | 1.44 | 2.74 | 0.91 | Upgrade |
EPS Growth | 69.38% | 63.33% | 45.83% | -47.45% | 201.10% | - | Upgrade |
Free Cash Flow | 540.69 | 468.37 | 373.28 | 235.3 | 297.98 | 52.95 | Upgrade |
Free Cash Flow Growth | 15.44% | 25.47% | 58.64% | -21.04% | 462.76% | - | Upgrade |
Free Cash Flow Per Share | 4.24 | 3.62 | 2.78 | 1.67 | 2.03 | 0.37 | Upgrade |
Gross Margin | 84.20% | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% | Upgrade |
Operating Margin | 57.92% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | Upgrade |
Profit Margin | 47.28% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | Upgrade |
FCF Margin | 45.87% | 46.13% | 45.01% | 35.65% | 67.22% | 19.79% | Upgrade |
EBITDA | 764.4 | 632.79 | 422.43 | 317.17 | 278.9 | 147.54 | Upgrade |
EBITDA Margin | 64.85% | 62.32% | 50.94% | 48.05% | 62.91% | 55.14% | Upgrade |
EBIT | 682.67 | 551.48 | 337.57 | 267.53 | 275.9 | 144.26 | Upgrade |
EBIT Margin | 57.92% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | Upgrade |
Effective Tax Rate | 19.48% | 20.29% | 19.16% | 18.80% | -62.04% | 0.17% | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.